PATL2 inhibitors are a class of chemical compounds that interact with the PATL2 protein, which is a member of the PATE (prostate and testis expressed) family. These proteins, including PATL2, are characterized by their expression in the male reproductive system, although they can be found in other tissues as well. PATL2, specifically, has been of interest due to its role in biological processes at the cellular level. The inhibitors targeting PATL2 are designed to bind selectively to this protein, thereby modulating its activity. The exact mechanism by which these inhibitors interact with the PATL2 protein may vary, but typically involves the blockade of the protein's active site or interference with its ability to interact with other cellular components. This interaction can lead to changes in the function of the protein, which in turn can have downstream effects on cellular processes. The design of PATL2 inhibitors is a complex task that requires a deep understanding of the structure and function of the protein, as well as the precise nature of its role within the cell.
The development and characterization of PATL2 inhibitors involve multiple disciplines, including chemistry, biochemistry, and structural biology. The process begins with the identification of the protein's structure, which is often achieved through techniques like X-ray crystallography or NMR spectroscopy. With this structural knowledge, chemists can design molecules that are complementary to the active site of PATL2 or its interaction surfaces. These inhibitors are typically small molecules that are crafted through a process of iterative design, synthesis, and testing to refine their ability to bind to the PATL2 protein with high specificity. Advanced computational methods, such as molecular docking and virtual screening, are frequently employed to predict how these small molecules will interact with the target protein and to identify promising candidates for further study. The physical and chemical properties of these inhibitors, such as their stability, solubility, and binding affinity, are important factors in their development. High binding affinity is often sought after, as it indicates a stronger interaction between the inhibitor and the protein, while optimal solubility and stability ensure that the inhibitor can function effectively within the complex environment of the cell.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
GW4869 | 6823-69-4 | sc-218578 sc-218578A | 5 mg 25 mg | $203.00 $611.00 | 24 | |
A neutral sphingomyelinase inhibitor that prevents the formation of ceramide, thereby influencing the endosomal sorting complex required for transport (ESCRT) machinery. This could impair the endosomal sorting and trafficking functions where PATL2 is implicated, leading to its functional inhibition. | ||||||
Bafilomycin A1 | 88899-55-2 | sc-201550 sc-201550A sc-201550B sc-201550C | 100 µg 1 mg 5 mg 10 mg | $98.00 $255.00 $765.00 $1457.00 | 280 | |
A specific inhibitor of the V-ATPase proton pump that disrupts endosomal acidification. Since PATL2 is involved in endosomal mRNA regulation, the inhibition of endosomal acidification can impair PATL2's ability to regulate mRNA in this compartment. | ||||||
Chlorpromazine | 50-53-3 | sc-357313 sc-357313A | 5 g 25 g | $61.00 $110.00 | 21 | |
Alkylates DNA and acts as a cationic amphiphilic drug that can inhibit clathrin-mediated endocytosis. By doing so, it may indirectly reduce PATL2's activity by preventing the proper trafficking of mRNA to endosomes. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
A small molecule inhibitor of the GTPase activity of dynamin, which is required for the scission of clathrin-coated vesicles during endocytosis. By inhibiting this process, Dynasore could decrease the functional activity of PATL2 by disrupting mRNA transport to endosomes. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $45.00 $164.00 $200.00 $402.00 $575.00 $981.00 $2031.00 | 46 | |
A tyrosine kinase inhibitor that can block phosphorylation events required for endocytosis. PATL2's activity could be hindered as a result of reduced endosomal trafficking of mRNAs. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
An ionophore that disrupts intracellular ion gradients and can affect endosomal pH. By altering the environment within endosomes, Monensin may indirectly inhibit PATL2's role in mRNA regulation within these compartments. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
A microtubule destabilizer that can interfere with intracellular trafficking. This could impede the transport of mRNAs to endosomes, potentially affecting PATL2's functional activity. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
An inhibitor of actin polymerization that disrupts cytoskeleton organization, which is critical for endocytosis and subsequent endosomal mRNA sorting, potentially inhibiting PATL2 activity. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
An inhibitor of myosin light chain kinase, which is involved in cytoskeletal dynamics. By inhibiting this kinase, ML-9 could indirectly inhibit PATL2 by affecting the transport of mRNA-containing vesicles to endosomes. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A PI3 kinase inhibitor that can disrupt various intracellular signaling pathways, including those involved in vesicle trafficking. This could lead to the inhibition of PATL2 by impairing the endosomal sorting of mRNAs. | ||||||